Acceleron reported strong progress in its pipeline, including completing enrollment in key Phase III trials and plans to initiate new studies. Management's optimistic outlook and secure financial position, bolstered by a significant fundraising, are likely to boost investor sentiment. Anticipation of upcoming trial results could lead to a positive short-term impact on the stock.

[1]